Thin-Shelled PEGylated Perfluorooctyl Bromide Nanocapsules for Tumor-Targeted Ultrasound Contrast Agent

Table 1

Characteristics of PFOB nanocapsules from different formulations (DLS measurement, per sample).

NC	Mixing ratio		Total polymer mass (mg)	dH (nm)	PDI	ζ (mV)
	PLGA (%)	PLGA-PEG (%)
NC10%	90	10	100	102.5 ± 0.4	0.249 ± 0.02	−46.2 ± 1.7
NC20%	80	20	100	130.0 ± 2.3	0.377 ± 0.01	−42.2 ± 2.9
NC40%	60	40	100	113.9 ± 4.2	0.306 ± 0.01	−44.7 ± 2.2
NC60%	40	60	100	134.7 ± 1.6	0.348 ± 0.02	−47.0 ± 1.8
NC80%	20	80	100	164.2 ± 4.9	0.426 ± 0.05	−42.5 ± 3.6
NCm20	60	40	20	95.6 ± 7.7	0.394 ± 0.01	−30.1 ± 2.3
NCm40	60	40	40	87.0 ± 2.1	0.266 ± 0.03	−29.8 ± 2.4
NCm100	60	40	100	156.6 ± 5.7	0.385 ± 0.03	−27.7 ± 1.3
Nonlabeled NCm100	60	40	100	120.1 ± 2.6	0.229 ± 0.02	−61.4 ± 0.9
Nonlabeled NCm100				101.8 ± 0.3	0.157 ± 0.01	−39.3 ± 0.6
Cetuximab-labeled NCm100	60	40	100	234.1 ± 2.3	0.328 ± 0.03	−50.0 ± 1.2
Cetuximab-labeled NCm100				159.2 ± 1.8	0.183 ± 0.02	−41.0 ± 2.6

Before and after being prepared for in vivo studies, by filtration and short sonication.